IMM vs. BVX, GENF, ROQ, BSFA, VAL, SNG, IXI, EVG, APTA, and FAB
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include BiVictriX Therapeutics (BVX), Genflow Biosciences (GENF), Roquefort Therapeutics (ROQ), BSF Enterprise (BSFA), ValiRx (VAL), Synairgen (SNG), IXICO (IXI), Evgen Pharma (EVG), Aptamer Group (APTA), and Fusion Antibodies (FAB). These companies are all part of the "biotechnology" industry.
BiVictriX Therapeutics (LON:BVX) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
ImmuPharma received 266 more outperform votes than BiVictriX Therapeutics when rated by MarketBeat users.
BiVictriX Therapeutics has higher earnings, but lower revenue than ImmuPharma. BiVictriX Therapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
ImmuPharma's return on equity of -59.06% beat BiVictriX Therapeutics' return on equity.
34.8% of BiVictriX Therapeutics shares are held by institutional investors. Comparatively, 21.1% of ImmuPharma shares are held by institutional investors. 36.7% of BiVictriX Therapeutics shares are held by insiders. Comparatively, 43.0% of ImmuPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
BiVictriX Therapeutics has a beta of -0.6, meaning that its share price is 160% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.
In the previous week, ImmuPharma had 1 more articles in the media than BiVictriX Therapeutics. MarketBeat recorded 1 mentions for ImmuPharma and 0 mentions for BiVictriX Therapeutics. BiVictriX Therapeutics' average media sentiment score of 0.68 beat ImmuPharma's score of 0.67 indicating that ImmuPharma is being referred to more favorably in the news media.
Summary
ImmuPharma beats BiVictriX Therapeutics on 8 of the 12 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
